The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, paediatric HIV, and malaria.

DNDi was established in 2003 by Médecins Sans Frontières/Doctors Without Borders (MSF), institutions of endemic countries like the Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council for Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The Special Programme for Tropical Disease Research (TDR) serves as a permanent observer. DNDi has its headquarters in Geneva, Switzerland, six regional offices in Brazil, Kenya, Democratic Republic of the Congo, India, Malaysia, and Japan, as well as an affiliate in the United States.

[www.dndi.org](http://www.dndi.org)
DNDi Portfolio is a balanced mix of projects combining existing drugs and projects progressing new chemical entities throughout the R&D pipeline. At the moment, DNDi’s portfolio includes six projects in the implementation phase, seven projects in the clinical stage, nine projects in the pre-clinical stage, and two projects in Discovery covering four of the six diseases on which DNDi is working.
In DNDi’s portfolio, the presence of pharmaceutical partners is dominant in the Discovery stage, in which we have the opportunity to access compound libraries in order to identify new molecules. However, we sincerely hope that these partnerships will continue throughout the development of the new class of compound, to clinical and implementation stages. It is crucial for DNDi to secure partnerships at these stages of the development of a treatment to ensure the access of new and better-adapted treatments to the patients in need.
To develop its activities and achieve its objectives, DNDi seeks diversified sources of funding – cash contributions, in-kind contributions, grants, sponsorships, and legacies – from individuals, governments, public institutions, companies, foundations, NGOs, and alternative mechanisms that share a commitment to DNDi’s vision and mission.

In addition to the resources already secured, EUR 216 million still needs to be raised to achieve DNDi’s mission to develop 11 to 13 treatments to treat neglected diseases by 2018.